Enveric Biosciences Inc. has announced new preclinical data supporting the non-hallucinogenic profile of its lead candidate, EB-003. EB-003 is designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects.